Taking into account that decreased expression of glutamate transporters on astrocyte surface during neuroinflammation may result in excessive extracellular glutamate and neurotoxicity, we have considered EAAT2 worthy of further investigation as potential MS biomarker. Here, SLC1A2 is linked to myeloid sarcoma.